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Colon targeted drug delivery is an active area of research for local diseases affecting the colon, as it improves the efficacy of therapeutics
and enables localized treatment, which reduces systemic toxicity. Targeted delivery of therapeutics to the colon is particularly advantageous
for the treatment of inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease. Advances in oral drug delivery
design have significantly improved the bioavailability of drugs to the colon; however in order for a drug to have therapeutic efficacy during
disease, considerations must be made for the altered physiology of the gastrointestinal (GI) tract that is associated with GI inflammation.
Nanotechnology has been used in oral dosage formulation design as strategies to further enhance uptake into diseased tissue within the colon.
This review will describe some of the physiological challenges faced by orally administered delivery systems in IBD, the important
developments in orally administered nano-delivery systems for colon targeting, and the future advances of this research.
From the Clinical Editor: Inflammatory Bowel Disease (IBD) poses a significant problem for a large number of patients worldwide. Current
medical therapy mostly aims at suppressing the active inflammatory episodes. In this review article, the authors described and discussed the
various approaches current nano-delivery systems can offer in overcoming the limitations of conventional drug formulations.
©2015TheAuthors.PublishedbyElsevier Inc.This is anopenaccess article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Key words: Colon targeted drug delivery; Nano-delivery systems; Oral administration; Inflammatory bowel disease; ColitisInflammatory bowel disease (IBD) is the umbrella term for a
group of chronic relapsing gastrointestinal (GI) diseases which
include ulcerative colitis (UC) and Crohn's disease (CD).1 While
UC and CD are considered distinct conditions, they can share
many clinical features and are both characterized by cycles of
relapsing and remitting mucosal inflammation. For UC, this
inflammation is confined to the colon, extends proximally from the
rectum and is continuous, in some cases involving the entire colon
(pancolitis). Crohn's inflammation can affect any region of the GI
tract, with the terminal ileum and the colon commonly affected.
The inflammation is generally discontinuous in manner.1
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targeting to diseased versus healthy tissue. Nanomedicine: NBM 2015;11:1117have been suggested to play a role, such as genetics, microbiome,
environmental stress and immune dysfunction.2
There is currently no cure for IBD, with therapeutic strategies
aimed toward attaining and maintaining remission from inflam-
matory episodes. Steroids are commonly prescribed for acute
exacerbations of both UC and CD, but prolonged use can lead to
undesirable systemic side-effects.3,4 Other therapies for IBD
include aminosalicylates, antibiotics, and immuno-suppressive
agents. While these medications can temporarily induce and
maintain remission, 70% of IBD patients will require at least one
surgical intervention in their lifetime.5,6 A systematic review by
Talley et al5 highlighted the variable performance of current IBD
therapies across IBD phenotype, location, stage and severity
of disease.
Conventional oral formulations are limited for use in IBD as
they are generally designed to achieve systemic delivery of
therapeutics, which results in adverse effects and toxicity
following distribution of drug around the body. Oral formula-
tions achieving a localized effect are preferred in rational drugder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Physiological and microbial changes to the GI tract in inflammatory bowel disease. IBD patients have increased orocecal transit times in the absence of
small intestinal bacterial overgrowth (SIBO).39 Tissue resection59 or SIBO39 can significantly reduce transit time. IBD patients exhibit minor elevation in small
intestinal pH,45,46 however there are significant decreases seen in the colonic pH of both CD and UC patients.21,47 These changes in pH and motility may
facilitate the widespread changes in commensal populations in the GI tract, affecting the small intestine and the colon.29,42
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to the site of action within the GI tract, but will not be absorbed
or will be poorly absorbed. Current therapeutic approaches
specifically indicated for IBD rely on conventional dosage forms
such as delayed or controlled release mechanisms. Their design
is based on exploiting physiological conditions in the GI tract, in
particular the colon.7 For example, prodrugs of 5-aminosalicylic
acid (5-ASA), such as sulfasalazine or olsalazine, rely on the
enzymatic activity of colonic bacteria to cleave the prodrug into
active moieties.8 Similarly non-starch polysaccharide coatings,
such as the COLAL-PRED® (prednisolone sodium metasulfo-
benzoate) system, and matrix formulations rely on enzymatic
degradation that is specific to colonic bacteria.9 Another
approach involves the use of pH-specific soluble coatings and
matrices, which rely on the pH gradient of the GI tract to activate
release,7 while time-dependent release systems use GI transit
times as a guide to activate release of the drug.10
These approaches are associated with inconsistent efficacy
and inter-patient variability.5 One reason for varied efficacy of
these conventional colon targeted delivery approaches may lie in
the diverse physiological changes and variability in the GI tract
that present with chronic and active inflammation in IBD
patients—including pH, GI transit time and the colonic
microbiome.5,11 Attempts to overcome these issues have focusedon improved understanding of the physiology of the GI tract
during active IBD and following GI tract resection, as well as
rational design of oral formulations. These considerations not
only improve biodistribution of therapeutics to the colon, but
also confer specific accumulation and cellular uptake within
diseased tissue.12,13 Recent pharmaceutical advances have
applied nanotechnology to oral dosage form design in an effort
to overcome the limitations of conventional formulations.14 This
review will describe some of the physiological challenges faced
by orally administered delivery systems in IBD, the important
developments in orally administered nano-delivery systems for
colon targeting, and the future direction of this research.General physiological considerations for colonic drug delivery
Drug delivery to the colon relies on a number of physiological
factors to ensure optimal efficacy following oral administration
(Figure 1). Considerations should be made during formulation
design to the residence time of the formulation in the GI tract,
how the GI environment affects the delivery of the formulation
and dissolution of the drug at the site of action, the intestinal fluid
volume, and the propensity of the formulation or drug to be
metabolised in the GI tract through enzymatic or microbial
1119S. Hua et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 1117–1132degradation. For instance, consideration of the formulation
transit time through the GI tract is critical to ensuring delivery of
the drug to the site of action.15 Small intestinal transit time is
generally accepted as 4 hours,16 with individual variability
ranging from 2 to 6 hours. In contrast, colonic transit times can
vary significantly, with ranges from 6 to 70 hours reported.17,18
Additional confounders influencing GI transit time include
gender, with females having significantly longer colonic transit
times,19 and the time of dosing with respect to an individual's
bowel movements.20
Differences in pH along the GI tract have been exploited for
the purposes of delayed release therapies. The highly acid
stomach environment rises rapidly to pH 6 in the duodenum and
increases along the small intestine to pH 7.4 at the terminal
ileum.21,22 Cecal pH drops below pH 6 and again rises in the
colon reaching pH 6.7 at the rectum.23,24 However, pH ranges
can exhibit variability between individuals, with factors such as
water and food intake as well as microbial metabolism being
major determinants.25 In addition to influencing pH, fluid:matter
ratios may also affect the colonic delivery of drugs. For instance,
free fluid volumes, bile salts and digestive enzyme levels in the
GI tract are significantly altered following food intake.26,27
Intestinal fluid secretion also affects the viscosity of the
mucous-gel layer, which may influence the ability of drugs to
be taken up by cells at the site of action.28
Finally, we are now appreciating the importance of the
intestinal microbiome in GI physiology. The GI tract plays host
to over 500 distinct bacterial species, with many estimating the
number of species to be close to 2,000.29 These bacteria play
pivotal roles in both digestion and intestinal health, including
digestion and metabolism of fatty acids, proteins and
carbohydrates.30 The majority of the intestinal microbiome resides
in the anaerobic colon and fermentation of carbohydrates is the
main source of nutrition for this population.30 The relatively
exclusive fermentation of non-starch polysaccharides by the
colonic microbiome is exploited in formulations that use
non-starch polysaccharide coatings.31 While there appears to be
considerable variation in the composition of the microbiome
between individuals, which is influenced by both genetic and
environmental factors,2 the dominant Firmicutes, Bacteroidetes,
Proteobacteria, andActinobacteria species appear to be consistent
and represent the majority of the colonic flora.32 Despite this, the
microbiome is exposed to temporal disruption (dysbiosis) by
disease and medications (e.g. antibiotics), and is influenced by
factors such as diet, lifestyle and geographical distinctions.2,33
It is therefore clear that within healthy individuals there is
variability in the physiology of the GI tract. Adding to this
complexity are the changes in physiology associated with GI
disease, which will further affect the efficacy of orally
administered formulations. These physiological factors are
dynamic, inter-related and remain an important challenge in
dosage form design. Depending on disease severity, gastroin-
testinal pathologies can affect some or all of the physiological
variables for oral drug delivery. Many acute GI infections will
cause dysbiosis34 and drive increased intestinal fluid secretion,35
and may increase or decrease bowel motility,36 while more
chronic conditions, such as IBD, can drastically and permanently
alter the physiology of the GI tract.Changes in the physiology of the GI tract during active IBD
An often overlooked confounder when considering oral
delivery strategies in IBD is the change in the physiological
condition of the GI tract associated with chronic inflammation.
Mucosal inflammation in IBD causes pathophysiological
changes, such as (i) a disrupted intestinal barrier due to the
presence of mucosal surface alterations, crypt distortions and
ulcers, (ii) increased mucus production and (iii) the infiltration of
immune cells (e.g. neutrophils, macrophages, lymphocytes and
dendritic cells).37,38 During relapse of IBD, patients suffering
from severe mucosal inflammation may exhibit altered GI
motility and diarrhea, which in turn affects intestinal volume, pH
and mucosal integrity. The inflammatory response at the mucosa,
along with severe diarrhea, will also disrupt the resident
microbiome, which can alter microbial metabolism in the GI
tract. Thus active inflammation significantly alters the physiol-
ogy of the GI tract (Figure 1), which can affect the efficacy of
conventional approaches to colon targeted drug delivery.
Transit time and microbial considerations
Alterations to GI physiology in states of disease are often
dynamic and inter-related, and therefore difficult to examine in
isolation. For instance, orocecal transit time (OCTT), the time
taken for the meal to reach the cecum, has been shown to be
delayed in both CD and UC patients compared to healthy
controls.39 However, significantly faster OCTTs have been
observed in IBD patients with the dysbiotic condition—small
intestinal bacterial overgrowth (SIBO). These observations have
been confirmed experimentally in humanized mice, following
dietary manipulation of the gut microflora.40
Changes in the composition of the microbiome (dysbiosis) are
common in GI disease, with alterations in physiology,
inflammatory state, or as a result of treatment regimens.41
While it is generally accepted that the bacterial load is relatively
static in IBD, the diversity of the microbiome is reduced with
increases in major species such as Bacteroides, Eubacteria and
Peptostreptococcus acting to the detriment of other
populations.42 It is not known what precipitates the initial
dysbiosis, and whether dysbiosis precedes or is a symptom of
disease. However, there is some evidence to suggest that
physiological factors such as dysmotility and increased luminal
fluid (diarrhea) may play a role. Studies in animal models have
shown that prolonged water secretion into the bowel, leading to
decreased colonic transit times, can alter the colonic
microbiome.43,44 Therefore, not only can the microbiome affect
intestinal transit times, but conversely, transit times may also
alter the intestinal microbiome.
In contrast to OCTT, colonic transit is significantly faster in
IBD patients, likely due to the diarrhea that is a hallmark of the
disease.1,11 UC patients may exhibit transit times twice as rapid
as a healthy individual, leading to difficulties in targeting specific
regions of the colon with conventional formulations. Studies
using conventional delayed release formulations have shown
asymmetric biodistribution in the colon, with higher retention of
drug in the proximal colon and significantly lower drug
concentrations in the distal colon.11 Thus transit time in itself
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in IBD.
Changes in colonic pH
There is little evidence to suggest major alterations to small
intestinal pH in IBD patients,45,46 however colonic pH is
significantly lower in both UC and CD patients. In the colon,
intestinal pH is influenced by microbial fermentation processes,
bile acid metabolism of fatty acids, bicarbonate and lactate
secretions, and intestinal volume and transit times.23 As all of
these factors may be disrupted during active IBD, changes in
luminal pH in the colon are not surprising. While normal colonic
pH ranges from 6.8 in the proximal colon and rises to 7.2 in the
distal colon, this can significantly vary in active UC patients
from pH 5.5 to as low as 2.3.21,47 Similarly, reported colonic pH
values for CD patients are approximately 5.3, irrespective of
disease activity.24 These pH changes are likely to affect the
composition of the colonic microbiome and thus colonic transit
times, which can influence the release of drug from formulations
requiring bacterial fermentation or enzymatic activity. Likewise,
pH changes can affect the release of compounds from
pH-dependant release coatings.
Intestinal volume
The composition of the intestinal biomass is altered in disease
and is directly related to changes in microbial metabolism,
intestinal transit time and luminal pH. In particular, increased
fluid secretion and decreased reabsorption can dilute the
digestive enzymes that control intestinal transit to allow nutrient
absorption.48 This in turn may influence the intestinal micro-
biome, which can alter carbohydrate and polysaccharide
digestion49 as well as contribute to changes in intestinal transit
times.48 These changes in intestinal fluid volumes may alter the
way conventional formulations are processed in the GI tract and
the subsequent local delivery of drugs to the colon.
Mucosal integrity
The epithelial barrier selectively regulates transport from the
lumen to the underlying tissue compartments,50 restricting
transport of smaller molecules across the epithelium, while
virtually abolishing macromolecule transport. This selectivity is
determined by apical transmembrane protein complexes known
as tight junctions (TJ). These multi-protein complexes interact
directly with underlying epithelium actomycin rings, influencing
physiological and pathophysiological stimuli, such as ion
transport, luminal glucose transport, water secretion and the
transport of cytokines and leukocytes.51 While these properties
make TJ an attractive pharmacological target for enhancing drug
absorption,52 dysfunctional regulation of TJ complex formation
is associated with a loss of epithelial integrity in intestinal
inflammatory diseases, such as IBD.50 Active inflammation not
only alters intestinal mucosal integrity, but also significantly
alters mucosal metabolism as the tissue attempts to limit further
damage and repair.53 For instance, in an attempt to compensate
for the loss of intestinal epithelial integrity accompanying
inflammation and tissue ischemia, a number of endogenous
protective pathways are activated subtly altering the physiologyof the mucosa. In order to augment intestinal barrier function,
and perhaps compensate for the reduction in mucous-gel
integrity with fluid secretion, the oxygen-sensing transcription
factor, hypoxia-inducible factor (HIF), mediates increased
expression of intestinal mucins and trefoil factors.53 The
viscosity of the mucous-gel layer is likely to affect the
permeability of lipophilic drugs and mucoadhesive
formulations.3 In addition, HIF transcriptionally regulates
multi-drug resistance gene 1 (MDR1), which codes for the
xenobiotic drug efflux pump, P-glycoprotein (P-gp), that is
involved in actively transporting substrate compounds back into
the lumen.54 For example, glucocorticoids are substrates for
P-gp and have been shown to stimulate the expression of MDR1,
potentially contributing to steroid resistance in IBD.55 Interest-
ingly, nano-delivery systems have been shown to target both
drug and biological mechanisms to overcome multidrug
resistance via P-gp inhibition and ATP depletion.56
Intestinal resection in IBD patients
Resection of bowel tissue is common among IBD sufferers,
with over 70% of IBD patients undergoing at least one surgery in
their lifetime.6 Removal of bowel tissue results in a shortening of
the intestine and reduced transit distance through the GI tract,
which potentially affects the way conventional oral formulations
are processed. Beyond this, resection profoundly changes the
physiology of the intestinal tract by altering pH, nutrient
absorption, digestion and transit.57-59 In particular, resection of
the terminal ileum alters water absorption and dilutes residual
bile acids in the colon, therefore reducing net colonic fatty acid
concentrations.60,61 This may profoundly alter microbial metab-
olism of fatty acids by hydroxylation to produce ricinoleic acid
analogues that can drive diarrhea.60,62 Diarrhea significantly
affects the therapeutic efficacy of conventional oral
formulations.63 The reduction in fatty acids also reduces the
“ileal brake”—a nutrient feedback mechanism which slows
transit times to allow nutrient absorption.48,64 As fatty acids are
the most potent stimulant of the ileal brake, a loss of both fatty
acid receptors (from resected tissue) and fatty acids from
digestion leads to a loss of the ileal brake65 and a subsequent
decrease in intestinal transit time. As a large proportion of IBD
patients have undergone resection of the bowel, these physio-
logical changes should be considered when devising targeted
delivery strategies in the GI tract.Current oral nano-delivery system strategies for drug delivery
to inflamed colon
Improved oral drug delivery design has drastically improved
the colonic bioavailability of drugs, that is, these formulations
are effective at reaching and releasing drug specifically in the
colon. However, in order for a drug to have therapeutic efficacy it
must be localized to the site of action within the colon.
Conventional oral formulations can be adversely affected during
active IBD or following intestinal resection, and have limited
efficacy and specificity for diseased colon tissue versus healthy
colon tissue.66 In addition, despite coverage of the colonic
surface (including diseased tissue), there is no guarantee that the
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inflammation.12 Pharmaceutical strategies utilizing nano-
delivery systems as carriers for active compounds have shown
promising results in addressing the physiological changes in
IBD, and exploiting these differences to enhance specific
delivery of drugs to diseased tissue.67,68 Therefore the use of
nanotechnology in formulation design may further improve the
efficacy of therapeutics by allowing inflammation-specific
targeting and uptake within the colon.
Nano-delivery systems have been designed to passively or
actively target the site of inflammation. These systems have been
shown to be more beneficial than conventional formulations,
because their size leads to more effective targeting, better
bioavailability at diseased tissues and reduced systemic adverse
effects. Hence, nano-delivery systems have been found to have
similar or improved therapeutic efficacy at lower drug
concentrations in comparison to conventional formulations.67,68
Although size is an important factor in targeting the colon,
additional strategies to enhance drug delivery to inflamed
intestinal mucosa and achieve maximal retention time in tissues
are being explored. This section will review current information
on the effect of size and then characterize the different
orally administered nano-delivery systems for IBD by their
pharmaceutical strategy for targeted drug delivery to inflamed
colonic tissue.
Size-dependent nano-delivery systems
Reducing the size of drug delivery carriers to the nanometer
scale has been shown to improve colonic residence time in
inflamed intestinal regions and provide additional benefits for
IBD therapy (Figure 2). This reduction in size enables enhanced
and selective delivery of active molecules into the colitis tissue
by exerting an epithelial enhanced permeability and retention
(eEPR) effect,67,68 and allows the preferential uptake of the
nano-sized particles by immune cells that are highly increased in
number at the inflamed regions.69 By reducing the diameter of
the particles, it is also possible to avoid rapid carrier elimination
by diarrhea, which is a common symptom in IBD.70 Nano-
delivery systems avoid rapid carrier elimination by being readily
taken up into inflamed tissue and cells. Conventional formula-
tions do not have this advantage as they are generally designed to
promote regional deposition of drug in the GI tract. Preferential
accumulation in inflamed tissue increases the local concentration
of therapeutics against IBD. Nanoparticles in the GI tract
generally undergo cellular internalization by paracellular trans-
port or endocytosis into epithelial cells in the GI tract. In IBD,
specialized differentiated epithelial cells called M cells are
involved in the predominant uptake of nanoparticles through
transcytosis. Translocation of nanoparticles can also occur by
persorption through gaps or holes at the villous tips.71-73
This accumulation is particle size dependent with an
increasing effect for smaller particle diameters.74 Lamprecht
et al74 investigated the significance of particle size on deposition
in the inflamed colon in the trinitrobenzenesulfonic acid induced
(TNBS) rat model of colitis. Studying fluorescent polystyrene
particles ranging in size from 0.1 to 10 μm, administered orally
for 3 days in vivo, highest binding to inflamed tissue was foundfor 0.1 μm particles (control healthy group: 2.2% ± 1.6%;
colitis: 14.5% ± 6.3%). The ratio of colitis/control deposition
increased with smaller particle sizes. Interestingly, after removal
of the mucus from the inflamed tissue through several washing
steps, the total fluorescence in the tissue decreased by ~39% for
the 0.1 μm particles. This suggests that a high proportion of the
particles were binding to the thick insoluble mucus layer rather
than being taken up by macrophages. It should be noted that the
nanoparticles in this study had a negative charge (negative zeta
potential), which is a characteristic in itself that would have an
influence on nanoparticle accumulation (discussed in Surface
charge-dependent nano-delivery systems).
This particle size dependent effect has been shown to be
independent of the nature of the carrier material itself, with a
number of studies demonstrating accumulation of ‘basic’
nanocarriers within inflamed colon tissue. The term ‘basic’ is
used to denote that no coating or conjugation mechanism or
surface property alterations were utilized to enhance colon
selectivity other than reducing particle size alone. The majority
of these reports have been limited to in vitro cell studies, ex vivo
tissue studies or in vivo animal studies following rectal
administration.75 While passive targeting with size enables
longer retention time and enhanced permeability, there have been
contradictory findings with regards to specificity to disease
versus non-diseased tissue. For example, nanoparticles prepared
with cetyltrimethylammonium bromide (CTAB) with a size of
200 nm and a relatively neutral charge, significantly adhered to
both non-inflamed colonic tissue in healthy controls as well as
inflamed colonic tissue in the TNBS colitis model following
rectal administration.76 Conversely, polylactide–coglycolide
nanoparticles (100 nm) encapsulating the immunosuppressant
drug, tacrolimus (FK506), was shown to significantly enhance
drug penetration into inflamed tissue in both the TNBS and
oxazolone (OXA) colitis model following rectal administration,
with a reduction in both myeloperoxidase activity and colon/
body weight ratio.69 The relative drug penetration into the
inflamed tissue was approximately 3-fold higher compared with
healthy tissue with the use of nanoparticles as drug carriers
ex vivo. The therapeutic effects of FK506-nanoparticles by the
oral route were minor. This was potentially attributed to slow
onset of drug release, degradation of the nanoparticle building
matrix polyester by digestive enzymes in the upper GI tract, or
systemic uptake and subsequent hepatic metabolism.
Interestingly, Schmidt et al77 investigated the potential of
nano- and microparticle uptake into the rectal mucosa of human
IBD patients and found an obvious accumulation of micropar-
ticles in active IBD, whereas nanoparticles were detectable only
in traces in the mucosa of these patients. They demonstrated that
microparticles exhibited accumulation and bioadhesion to the
inflamed mucosal wall; however no absorption of these particles
across the epithelial barrier was detected. Conversely, nanopar-
ticles were translocated to the serosal compartment of IBD
patients, possibly leading to systemic absorption. The study
suggested that nanoparticles might not be required for local drug
delivery to intestinal lesions in humans. The reason for the
discrepancy of particle size between animal and human studies is
unclear; however, it may be of major importance in the future
treatment of human IBD. It should be noted that while particle
Figure 2. Characteristic changes to the mucosal barrier in inflammatory bowel disease. The healthy mucosa (A) is protected by an inner adherent and outer
mobile mucous-gel layer, which acts as a barrier to large molecules and hydrophobic compounds.28 Underneath the mucous layer, a selectively permeable
epithelial barrier allows nutrient absorption while excluding bacteria and luminal contents from the serosa. Antigen sampling is performed by Microfold (M)
cells overlying lymphoid follicles. These M cells have a reduced or absent mucous-gel layer,28 and may be targeted by nanoparticles.72,73 Mucosal inflammation
(B) is associated with a loss of both the inner adherent and outer mobile mucous-gel layers, loss of epithelial barrier integrity through enterocyte damage, and
increased translocation of intestinal bacteria leading to a recruitment of immune cells to the mucosal tissue. These changes lead to a preferential accumulation and
uptake of nanoparticles by both enterocytes and macrophages, including increased exposure of inflammatory receptor targets to nanoparticles.
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total fraction of particles penetrating into the mucosa was
relatively low in the study.
While cumulative results to date confirm that reduction in
particle size is essential for targeting colitis, the concept that
‘basic’ nanoparticles when administered by the oral route are
expected to accumulate specifically in inflamed colonic tissue
over non-inflamed tissue has not been proven when taken into
in vivo animal studies. To improve the effectiveness of
nano-delivery systems administered orally, other mechanisms
for maximising delivery of encapsulated therapeutics to areas of
colitis, including altering surface properties, have been studied to
enhance colon selectivity and diseased tissue specificity in vivo.
Surface charge-dependent nano-delivery systems
Relatively little is known about how physicochemical
parameters of drug carriers, other than particle size, influences
adhesion to inflamed intestinal tissue. In particular, conflicting
results have been reported on the influence of surface charge to
colonic targeting, with results predominantly based on ex vivo
tissue binding studies or in vivo studies following rectal
administration. Modifying the surface charge of nano-delivery
systems can influence the electrostatic interaction the nanocar-
riers have with components in the GI tract and theoretically
should confer selectivity to diseased tissue. It should be noted
however, that there is a potential for electrostatic interactions and
subsequent binding of these nanoparticles with other charge-
modifying substances during GI transit (e.g. bile acids and
soluble mucins). Therefore it is likely that additional pharma-
ceutical strategies are needed, in addition to surface charge, in
order to localize drug delivery specifically to diseased
colitis tissue.
Positively charged nano-delivery systems—mucoadhesives
Several studies have revealed a major influence by the
cationic surface of nanoparticles on the deposition pattern and
therapeutic efficiency in IBD.78,79 Cationic nano-delivery
systems adhere to the mucosal surface within inflamed tissue
due to the interaction between the positively charged nanocarrier
and the negatively charged intestinal mucosa.14 Colonic mucins
carry a negative charge since their carbohydrates are substituted
with numerous sulfate and sialic acid residues.38,80 Adhesion to
the mucosa can be an advantage for GI tract targeting as it
promotes better contact with the mucosal surface for cellular
uptake and drug release. It can also reduce the clearance of
nanocarriers when intestinal motility is increased, which is
common in IBD.78,81 An increase in mucus production is also
observed in Crohn's disease, leading to a thicker mucus layer in
particularly ulcerated areas, making mucoadhesion a promising
strategy to increase targeting and retention of drug delivery
systems in colitis.38,68
In support of mucoadhesive nano-delivery systems, Niebel et
al82 investigated the efficacy of rectally administered clodrona-
te-loaded nanoparticles (120 nm) comprising cationic poly-
methacrylate (Eudragit RS) in the TNBS and OXA models of
colitis. Although clodronate alone was ineffective in experimen-
tal colitis therapy, its association with cationic nanoparticles
enabled alleviation of the inflammatory response in both colitismodels. Interestingly, it was observed that the therapeutic
potential of Eudragit RS nanoparticles could have been greater
if not for the nanoparticles being immobilized in the mucus,
rather than penetrating the mucus layer and reaching and
adhering to the inflamed mucosa for uptake into epithelial cells
or immune cells. Interaction with mucin impeded the transport of
cationic nanoparticles through the mucus layer and additionally
risked premature drug release by an ion exchange mechanism.
Similar results were seen by Lautenschlager et al83 that assessed
the ex vivo targeting potential of chitosan-functionalised
poly(lactic-co-glycolic acid) (PLGA) nanoparticles (300 nm) to
human intestinal mucosa. The study showed that nanoparticles
were able to adhere onto the tissue surface, however minimal
particle translocation and deposition was detected in both
inflamed (6.2% ± 2.6%) and healthy tissue (5.3% ± 2.3%).
This was thought to be due to the strong electrostatic adhesion
to the negative mucosal surface, thus preventing translocation
into the tissue. In inflamed tissues, the particles showed a low
particle penetration into the tissue, caused by adhesion into the
mucosal gaps. This result is further supported by the ex vivo
study conducted by Coco et al,14 using mucoadhesive
nanoparticles comprised of trimethylchitosan (TMC) on in-
flamed mouse colon tissue. Therefore this approach might be
useful for drugs that act on extracellular domains or only act after
uptake into immune cells in active inflammation.
Conversely, research into chitosan- and pectin-coated lipo-
somes have demonstrated enhanced drug uptake in vitro on
Caco-2 intestinal cells, ex vivo on excised intestinal tissue, and
in vivo using animal models of colitis, compared to uncoated
liposomes.78,84–87 For example, Thirawong et al88 evaluated the
mucoadhesion and uptake of orally-administered pectin-
liposome nanocomplexes (PLNs) in vivo in healthy Wistar rats
that had been fasted for 48 hours. The study demonstrated
increased residence of these nanoparticles in the GI tract mucosa,
with very little colloidal aggregation; however the majority of the
formulation was found to accumulate in the small intestine, with
little uptake in the colon. Therefore additional pharmaceutical
strategies are potentially needed in addition to surface charge
in order to localize drug delivery specifically to diseased
colitis tissue.Negatively charged nano-delivery systems—bioadhesives
Anionic nano-delivery systems were designed to preferen-
tially adhere to inflamed tissue via electrostatic interaction with
the higher concentration of positively charged proteins in
inflamed regions. In particular, high amounts of eosinophil
cationic protein and transferrin have been observed in inflamed
colon sections of IBD patients.89-91 However in order to reach
the inflamed tissue, the drug delivery system would need to
penetrate the thicker mucus layer overlaying the inflamed areas.
Irrespective of surface charge, smaller particles tend to show
improved adherence to the mucus layer due to an easier
penetration into the layer with respect to their relatively small
size.74,92 Rather than immobilization following binding to the
mucus (as seen with cationic nanoparticles), anionic nanoparti-
cles are able to interdiffuse among the mucus network due to less
electrostatic interaction with the mucus.
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multilamellar liposomes (800 ± 50 nm) on inflamed tissue from
the dinitrobenzene sulfonic acid (DNBS)-induced colitis model
showed a preferential adherence of negatively charged liposomes
to inflamed tissue, with a 2-fold higher adherence compared to
neutral or cationic liposomes.93 The adherence of negatively
charged liposomes was dependent on the concentration of DSPG
used in the liposomal formulation and hence the negative charge
density. Cationic and neutral particles showed no significant
binding to the inflamed intestinal areas; however three times as
many cationic liposomes adhered to the healthy colonic mucosa
than neutral or anionic liposomes. Conversely, Lautenschlager
et al83 assessed the ex vivo targeting potential of negatively
charged poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(300 nm) to inflamed human intestinal mucosa. These anionic
nanoparticles adhered onto the tissue surface and showed similar
bioadhesion to inflamed (9.4% ± 5.2%) and healthy tissue
(7.4% ± 6.3%) as compared to positively charged chitosan-
functionalized nanoparticles. It should be noted that both of these
studies examined the specificity of binding of nanoparticles
under ex vivo conditions, which may not be comparable to an
in vivo situation in IBD.
In vivo studies have shown promising results for anionic
nano-delivery systems in IBD. For example, Beloqui et al70
demonstrated that anionic nanostructured lipid carriers (NLCs)
loaded with budesonide (200 nm) significantly reduced inflam-
mation in the dextran-sulfate (DSS)-induced colitis model
following oral gavage. NLCs are considered second-generation
solid lipid nanoparticles (SLN) with higher stability and drug
loading capacity.94 The budesonide-loaded NLCs were able to
decrease neutrophil infiltration, decrease the levels of pro-
inflammatory cytokines in the colon and reduce histological
disease in the colon. Even after DSS challenge in mice and in
mice subjected to severe diarrhea, higher amounts of NLCs were
observed in the colon 12 h after administration. It should be
noted that overall, high amounts of the fluorescent-labeled NLCs
were also detected in the small intestine of DSS-treated mice and
in the colon of healthy control mice. The NLCs were reported to
penetrate the mucosae in DSS-treated mice, in comparison to
accumulating at the surface of the villi in healthy control mice.
Recently, an in vivo study investigating the fate of negatively
charged NLCs (150 nm) following oral administration in healthy
animals determined the pharmacokinetics and biodistribution of
the NLC nano-delivery carrier.95 The study showed localization
mainly in the small intestine and retention of the nanocarriers
in the underlying epithelium, allowing further uptake by
epithelial cells.
In addition, Meissner et al96 showed that the in vivo
therapeutic efficacy and reduction in adverse effects of
tacrolimus (FK 506)-loaded PLGA nanoparticles were similar
to tacrolimus-loaded pH-sensitive nanoparticles (composed of
Eudragit P-4135F) (both 450 nm) in the DSS-induced colitis
model. Compared to PLGA nanoparticles, pH-sensitive nano-
particles exhibited a lack of specificity; however they had
comparatively lower drug leakage and higher total amount of
tacrolimus delivered to the colon. Conversely, PLGA nanopar-
ticles increased drug concentration specifically inside the
inflamed tissue, with a lower total amount of drug delivered.Degradation of PLGA nanoparticles during passage in upper
parts of the intestine may enhance the potential for adverse
effects. Similar alleviation of colitis was reported by Lamprecht
et al92 following oral administration of rolipram-loaded PLGA
nanoparticles in the TNBS-induced colitis model. The nanopar-
ticle system enabled the drug to accumulate in the inflamed
tissue with higher efficiency than when given as a solution,
which allowed continued reduction in inflammation following
cessation of treatment. Although the results to date are promising
for the specificity of anionic nano-delivery systems to diseased
tissue, it appears that additional approaches may be required to
improve bioavailability into the colon.
PEGylation-dependent nano-delivery systems
The use of poly(ethylene glycol) (PEG) on the surface of
nanoparticles creates a hydrophilic surface chemistry that
reduces interaction of the PEG-functionalized nanoparticles
with the intestinal environment, therefore enabling an almost
unhindered diffusion through the disturbed epithelium.97-99 PEG
is a hydrophilic and uncharged molecule that has properties
which minimize a strong interaction with the mucus constituents,
and increases particle translocation through the mucus as well as
mucosa.97 In particular, low molecular weight PEG has been
shown to provide an effective shield of the hydrophobic core of
the particles, while minimizing interpenetration or intermolec-
ular interactions between PEG polymers and luminal
surrounding.83,98 This hydrophilic surface provides an acceler-
ated translocation into the leaky inflamed intestinal epithelium,
which is ideal for colitis targeted drug delivery.83
Lautenschlager et al83 assessed the ex vivo targeting potential of
PEG-functionalized PLGA nanoparticles (300 nm) and micropar-
ticles (3000 nm) to inflamed human intestinal mucosa. Surface
modification of nanoparticleswith PEGdemonstrated significantly
enhanced particle translocation and deposition in inflamed
mucosal tissues compared to chitosan- and non-functionalized
PLGA particles. PEG-functionalized microparticles showed
significantly increased translocation through inflamed mucosa
(3.33%) compared to healthy mucosa (0.55%, P = 0.045), and
significantly increased particle deposition in inflamed mucosa
(10.8%) compared to healthy mucosa (4.1%, P = 0.041).
Interestingly, PEG-functionalized nanoparticles showed the high-
est translocation through inflamed (5.27%) and healthy mucosa
(2.31%, P = 0.048). Particle deposition was also higher in
comparison to PEG-functionalized microparticles, however there
was no significant difference between depositions in inflamed
mucosa (16.7%) compared to healthy mucosa (13.7%).
In addition, Vong et al100 designed a novel nitroxide
radical-containing nanoparticle (RNPO), which possesses anti-
oxidative nitroxide radicals in the core for treatment of mice with
DSS-induced colitis. In several experimental models, antioxidant
compounds and free radical scavengers have improved colitis;
however are associated with significant bioavailability and
retention issues.101-103 Therefore these nanoparticles were
designed to deliver antioxidant compounds specifically to
diseased tissue for treatment of IBD. RNPO contains a
new redox polymer, methoxy-poly(ethylene glycol)-b-poly(4-
[2,2,6,6-tetramethyl-piperidine-1-oxyl]oxymethylstyrene
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with stable nitroxide in a hydrophobic segment as a side chain
via an ether linkage, and forms 40 nm sized core shell-type
micelles (RNPO) by self-assembly in aqueous environments
regardless of pH. RNPO showed significant accumulation in the
colonic mucosa, especially the inflamed mucosal tissue,
in comparison to control 4-hydroxyl-2,2,6,6-tetramethyl-
piperidine-1-oxyl (TEMPOL) or polystyrene latex particles,
and did not undergo systemic absorption despite its long-term
retention in the colon. Accumulation of RNPO in the colon was
observed to be almost 50 times higher than that of TEMPOL.
Mice with DSS-induced colitis had significantly lower disease
activity index and less inflammation following 7 days of oral
administration of RNPO compared to mice given TEMPOL or
mesalamine. The accumulation of RNPO in the colon was
dependent on both the size and PEGylated character of the
nanoparticles. The PEGylated character of RNPO was thought to
protect nitroxide radicals in the hydrophobic core from harsh
conditions in the GI tract after oral administration, resulting in
significant accumulation in the colon area.104 Furthermore, PEG
chains may achieve mucoadhesion due to their ability to
interdiffuse among the mucus network and polymer entangle-
ment with mucin, which is composed of glycoprotein.99 Despite
a limited number of studies, those to date support PEGylation as
a promising pharmaceutical strategy for accumulation in
inflamed colonic mucosa in IBD.
pH-dependent nano-delivery systems
This pharmaceutical strategy takes advantage of the difference
in pH in various regions of the GI tract. The pH in the terminal
ileum and colon is generally higher than in any other region of the
GI tract21,22; therefore a dosage form that disintegrates
preferentially at high pH levels has potential for site-specific
delivery into the colon. One of the simplest ways to modify
dosage forms for pH-dependent drug delivery is to coat themwith
pH-sensitive biocompatible polymers.105 In addition to trigger-
ing release at specific pH range, the enteric-coating protects the
incorporated active agents against the harsh GI tract environment
(e.g. gastric juice, bile acid and microbial degradation), and
creates an extended and delayed drug release profile to specific GI
tract regions to enhance therapeutic efficiency.
The most commonly used pH-dependent coating polymers
for oral delivery are methacrylic acid copolymers (Eudragit®).
By varying their side-group composition Eudragits® can be
manipulated to alter the pH at which they are soluble. Eudragit
L100 and Eudragit S100, which dissolve at pH 6 and 7
respectively, are commonly used in combination in various
ratios to manipulate drug release within the pH 6 to 7 range.15
Eudragit FS 30D is one of the more recently developed polymers
and dissolves at pH above 6.5. It is an ionic co-polymer of
methyl acrylate, methyl methacrylate and methacrylic acid and is
increasingly used for colon targeted drug delivery.15 In addition
to its pH-dependent release strategy, Eudragit® coatings have
also been suggested to have mucoadhesive properties. Karn
et al106 demonstrated that liposomes coated with Eudragit® have
superior mucoadhesion characteristics in freshly extracted pig
intestinal tissue, compared to other commonly investigatedpolymer coatings such as chitosan and carbopol. The results
suggest that Eudragit® coatings may enable pH-dependent
release and possibly reduce formulation clearance to enhance
colon targeted drug delivery.
Eudragit®-coated nano-delivery systems have demonstrated
favorable pH-dependent release characteristics in vitro.107,108
For example, Barea et al109 reported a significant reduction in
drug release from Eudragit®-coated liposomes in solutions
designed to simulate the pH conditions of the stomach and small
intestine. Drug release was equivalent to the uncoated control at
pH 7.8, indicating that the formulation displayed appropriate pH
responsive release characteristics. A further assay tested the
stability of the Eudragit-coated liposomes in simulated small
intestine fluid with the addition of biologically relevant
quantities of bile salts. The coating layer was not able to
withstand the additional challenge of bile salts, which would
potentially adversely affect its stability in vivo, causing
premature degradation of the liposomes and release of the drug
in the duodenum.
The potential instability of liposomes in the GI tract has led to
development of polymer-based carriers for colon-specific drug
delivery. A number of in vivo studies have investigated the use of
pH-dependent polymer-based nano-delivery systems for colon
targeting in IBD. Makhlof et al110 investigated budesonide-loaded
pH-sensitive nanospheres in the TNBS colitis model. The
nanospheres (260-290 nm) were prepared using polymeric
mixtures of PLGA and Eudragit® S100. In vivo experiments
demonstrated superior therapeutic efficacy of budesonide-loaded
nanospheres in alleviating colitis compared to that of conventional
enteric-coated microparticles (1.97 ± 0.78 μm). Nanospheres
showed higher colon levels and lower systemic bioavailability,
as well as specific adhesion to the ulcerated and inflamed mucosal
tissue of the rat colon. Similarly, Kshirsagar et al111 formulated
polymeric nanocapsules of prednisolone with Eudragit® S100
(567 nm) and demonstrated pH-dependent release in vitro over a
time period corresponding to normal physiological GI transit.
Nanocapsules have a polymeric wall enveloping an oil core and
generally have a lower polymer content and higher loading
capacity for lipophilic drugs in comparison to nanospheres.112
Pharmacokinetic studies in healthy rats did not show a rise in
plasma concentration for up to 3 h, and the increase in drug
concentration thereafter indicates dissolution of the nanocapsules
and release of the drug in the colon.
Several studies have thoroughly evaluated the clinical
outcomes following treatment with pH-dependent nano-delivery
systems in colitis, giving a good indicator of translational
applicability other than biodistribution. For example, Ali et al113
showed that budesonide-loaded PLGA nanoparticles coated with
Eudragit® S100 (~240 ± 14.7 nm) were able to significantly
alleviate inflammation and demonstrated signs of regeneration in
the DSS, TNBS and OXA in vivo models. More specifically, the
general endoscopic appearance of the groups treated with the
coated PLGA nanoparticles was similar to the healthy mice
groups, with no severe signs of inflammation as opposed to the
remaining control groups (inflamed control, budesonide solution
and plain PLGA NP). The coated PLGA nanoparticles also
showed significant down-regulation of pro-inflammatory cyto-
kines expression (TNF-α, IL-6, IL-1β, IFN-γ) in the colons.
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curcumin using pH-sensitive polymeric nanoparticles (166 nm)
composed of PLGA and Eudragit® S100 (CC-NPs) both in vitro
and in vivo. CC-NPs significantly enhanced drug permeation
across Caco-2 cell monolayers when compared to free drug in
suspension. In addition, CC-NPs significantly reduced neutro-
phil infiltration, TNF-α secretion and histological disease in the
colon of DSS-treated mice following oral gavage. It should be
noted that a higher accumulation of curcumin was seen in both
healthy and DSS-treated mice when encapsulated in nanoparti-
cles compared to the free drug suspension. Similarly, Lamprecht
et al115 designed tacrolimus (FK506)-loaded PLGA nanoparti-
cles entrapped into pH-sensitive microspheres (NPMS) to
achieve greater selectivity to the colon. Nanoparticles were
coating with Eudragit® P-4135F. In vivo studies in the TNBS
colitis model demonstrated significant reduction in the colon/
body weight index and myeloperoxidase activity only in the
NPMS group (colitis control: 21.94 ± 4.97; FK506 solution:
15.81 ± 3.42; FK506-NP: 17.03 ± 5.52; FK506-MS: 15.17 ±
7.81; and FK506-NPMS: 10.26 ± 7.76 U/mg tissue), which
indicates a reduction in the severity of inflammation. The NPMS
system also showed reduced systemic absorption, thus confer-
ring a local and selective delivery of NP in the colon.
Although preclinical studies of pH-dependent nano-delivery
systems for colon targeting have been promising, a major concern
has been the inherent inter-individual and intra-individual
variability of pH and emptying times from the GI tract, as well
as the change in luminal pH due to disease state. A colonic
delivery system that is based only on GI transit time or pH of the
GI tract would simply not be reliable for IBD. Studies in human
volunteers have shown that since the pH drops from 7.0 at the
terminal ileum to 6.0 of ascending colon, such systems sometimes
fail to release the drug.15 The potential for degradation of the
Eudragit® coating by bile acids in the duodenum also requires
further investigation.
Biodegradable nano-delivery systems in the colon
Having an understanding of the physiological variability in
IBD, such as pH and GI transit time, biodegradable nano-
delivery systems were devised to take advantage of other factors
that are known to be more consistent in IBD patients to allow
efficient colon-targeted drug delivery. Laroui et al13 developed a
hydrogel that is specifically degraded by enzymes in the colon at
pH 6.2, using ions (Ca2+ and SO42−) that cross-link chitosan
and alginate. The hydrogel was embedded with nanoparticles
containing an anti-inflammatory tripeptide Lys–Pro–Val (KPV)
(400 nm). Under the protection of the hydrogel, particles were
able to pass through the stomach and upper small intestine, and
were degraded in the inflamed colon. Encapsulated KPV-loaded
nanoparticles in hydrogel, administered by oral gavage,
efficiently reduced the severity of colitis in the DSS colitis
model, as shown by a reduction in myeloperoxidase activity and
histologic examination. Using this improved oral nanoparticle-
based drug delivery system, a 1200-fold lower dose was
sufficient to ameliorate mucosal inflammation in vivo compared
to KPV in free solution. It should be noted that the biomaterial
used in the study was composed of chitosan, which is a cationicpolymer with mucoadhesive properties. This may have increased
the therapeutic efficacy of the formulation following enhanced
delivery into the colon by the novel hydrogel.
To bypass the degradative effects of components in the GI
tract, recent studies have also embedded nano-delivery systems in
hydrogel (chitosan/alginate) that selectively degrades in the
vicinity of the inflamed colon. For example, Laroui et al116 used
hydrogel to embed siRNA in nanoparticles for IBD therapy. Oral
administration of CD98 siRNA/polyethyleneimine (PEI)-loaded
nanoparticles (~480 nm) encapsulated in hydrogel reduced
CD98 expression in mouse colonic tissues and decreased
DSS-induced colitis in a mouse model. Flow cytometry showed
that CD98 was effectively down-regulated in the intestinal
epithelial cells and intestinal macrophages of treated mice.
Similarly, Xiao et al117 used hydrogel (chitosan/alginate) to
deliver CD98-targeted nanoparticles loaded with CD98 siRNA
(discussed in Active targeting-dependent nano-delivery systems).
Another unique colon-targeted nano-delivery system is
the nanoparticle-in-microparticle oral delivery system
(NiMOS).118-120 NiMOS are designed for oral administration
of plasmid and siRNA by encapsulating them in type B gelatin
nanoparticles, which are further entrapped in poly(epsilon-
caprolactone) (PCL) microspheres. PCL is a synthetic hydro-
phobic polyester that is resistant to degradation by acid, therefore
protecting nanoparticles during transit through the stomach. In
addition, the coated microparticles are able to inhibit protein/
enzyme adsorption, thereby avoiding the harsh environment of
the GI tract. Release of the payload carrying nanoparticles occurs
over time at inflamed sites in the intestine, via controlled
degradation of the outer PCL layer by action of lipases
abundantly present at this location, after which they can be
endocytosed by enterocytes or other cells at these sites.120 This
multicompartmental biodegradable polymer-based nano-
delivery system has been used to deliver TNF-α siRNA,118 as
well as a combination of siRNA duplexes specifically targeted
against TNF-α and cyclin D1 (Ccnd1).119 NiMOS loaded with
siRNA demonstrated successful gene silencing and significantly
reduced inflammation in the DSS-induced colitis model.
In addition, silica nanoparticles (SiNP) have been modified to
have selective drug delivery toward inflamed tissue in chronic
inflammatory diseases of the intestine.121 SiNPs have been
widely used in the biomedical field as a pharmaceutical excipient
for oral drug delivery. Typically when used as medication
carriers, drugs are adsorbed onto the surface of the nanoparticles
and release triggered by simple desorption kinetics; which are
poorly controllable in complex biological media (e.g. blood and
GI juices).122 To combat premature release of drug compounds
that are physically entrapped or adsorbed to nano-delivery
systems, Moulari et al121 covalently bound the anti-inflammatory
drug, 5-aminosalicylic acid (5ASA), to the surface of modified
SiNP (Me5ASA-SiNP) (140 nm). The resulting chemical bond is
biodegradable and intended to considerably delay drug release.
Me5ASA–SiNP for drug delivery in IBD combines therapeutic
approaches of passive drug targeting by nanoparticles, and the
triggered release from a prodrug retaining the entrapped drug
following selective accumulation in the inflamed tissue. The
chemical modification of the SiNP surface involves the
integration of hydrophobic chemical entities, which makes the
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density of Me5ASA on the surface, which itself may act to inhibit
accessibility to enzymes for steric reasons. These modifications
delay drug release until the nanoparticles accumulate within
inflamed regions of the colon, where drug release is then triggered
following enzymatic degradation of the peptide bonds between
the SiNP and Me5ASA. It has been suggested that the enzymatic
cleavage of Me5ASA into 5ASA is potentially triggered by
esterases; however under in vivo conditions various other
mechanisms may be involved. In vivo studies in the TNBS-
induced colitis model demonstrated selective accumulation in the
inflamed colonic tissues following oral administration, with a
6-fold higher adhesion compared to healthy control groups.
Me5ASA–SiNP also significantly reduced inflammation at a
much lower dose compared to 5ASA-solution.
Redox nano-delivery systems
This pharmaceutical strategy for targeted drug delivery to
diseased colonic tissue takes advantage of the abnormally high
levels of reactive oxygen species (ROS) produced at the site of
intestinal inflammation. For example, biopsies taken from
patients suffering from ulcerative colitis have a 10- to 100-fold
increase in mucosal ROS concentrations, which are confined to
sites of disease and correlate with disease progression.123,124 The
unusually high concentrations of ROS localized to sites of
intestinal inflammation are generated by activated phagocytes.125
Taking advantage of this increased ROS concentration in
diseased tissue in IBD, Wilson et al126 synthesized thioketal
nanoparticles (TKNs) as a delivery vehicle for siRNA. TKNs are
formulated from a polymer, poly(1,4-phenyleneacetone dimethy-
lene thioketal) (PPADT) that degrades selectively in response to
ROS. PPADTwas used to encapsulate TNF-α siRNA complexed
with the cationic lipid, 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), to form nanoparticles. Complexing siRNA
with cationic species, such as DOTAP, enhances siRNA
transfection by increasing siRNA stability, mucosal transport,
cellular internalisation and endosomal escape.127,128 Further-
more, incorporating DOTAP confers nanoparticles with a
positive surface charge, which can increase particle uptake by
phagocytes129 and adhesion to the negatively charged intestinal
mucosa.38 TKNs showed selective localization of orally
delivered siRNA, against the proinflammatory cytokine TNF-α
(0.23 mg siRNA/kg/day), to sites of intestinal inflammation in
the DSS-induced colitis model. These nanoparticles significantly
suppressed mRNA levels of TNF-α and several other pro-
inflammatory cytokines (IL-1, IL-6 and IFN γ) in colon tissues,
while also reducing colonic inflammation as measured by histology.
In contrast, mice receiving DSS and treated with controls, including
TNF-α-PLGA (anionic) and TNF-α-DOTAP (cationic), showed all
of the characteristics of DSS-induced inflammation as measured by
histology, high levels of myeloperoxidase activity and significant
weight loss. These results support the ability of TKNs to target
inflamed tissues as an important factor for their in vivo efficacy.
Active targeting-dependent nano-delivery systems
Active targeting approaches using ligands coupled to the
surface of nano-delivery systems may increase therapeuticefficiency and reduce adverse reactions, by further improving
selective drug accumulation at inflamed siteswithin the colon. This
approach has been used to exploit disease-induced changes in the
expression of receptors, adhesion molecules and proteins on the
cellular surface of tissues affected by disease.12,130 The vast
majority of research in active targeting-based nano-delivery
systems has been studied using the parenteral route of adminis-
tration to target a multitude of conditions, such as cancers,
infections and sites of inflammation.131,132 With such positive
outcomes, it was inevitable for researchers to attempt this
pharmaceutical strategic approach for orally administered nano-
delivery systems. Monoclonal antibodies and peptides are
commonly used as targeting moieties, as they have been shown
to have high specificity in targeting and potential mucopenetrative
properties.133 It should be noted that oral administration of
antibody and peptide-based formulations encounter many obsta-
cles in the GI tract, in particular degradation by the stomach acid as
well as by enzymes; therefore these nano-delivery systems may
require further formulation design. This pharmaceutical strategy is
based on the concept that interactions between targeting ligands
and specific receptors expressed predominantly at inflamed sites
would improve bioadhesion of the drug formulation to specific
cells and increase the extent for endocytosis.
An increasing number of targeting ligands have been studied
for oral colon-specific drug delivery strategies. Mane and
Muro134 evaluated the biodistribution and cellular uptake of
polystyrene nanoparticles coated with anti-ICAM-1 antibodies in
the GI tract, following oral administration, in wild-type C57BL/6
mice using fluorescence and radiolabeling. As expected,
approximately 60% of the antibody dose administered (1.1 mg
antibody per kg) was degraded, which was attributed mainly to
GI tract enzymes. The nanoparticles were deposited mainly in
the stomach and duodenum, which suggest more upper GI tract
targeting. Transmission electron microscopy and energy disper-
sive X-ray spectroscopy were used to show endocytosis of the
radiolabeled anti-ICAM-1 nanoparticles within duodenal tissue
via ICAM-1. It should be noted that biodistribution of these
targeted nanoparticles was not evaluated in an animal model of
colitis. ICAM-1 is known to be significantly upregulated in
inflamed regions of the colon in IBD,135-138 with most prominent
expression on the surface of inflamed intestinal mucosal tissues
and microvasculature.139,140
Macrophage receptors have been another target for orally
administered nano-delivery systems for IBD. Mannose receptors
and macrophage galactose-type lectin (MGL) are highly
expressed by activated macrophages under inflammatory
conditions.141,142 Xiao et al143 synthesized a mannosylated
bioreducible cationic polymer (PPM) that was formed into
nanoparticles with sodium triphosphate (TPP) and TNF-α
siRNA by electrostatic interaction (TPP-PPM/siTNF NPs). The
nanoparticles showed an enhanced siRNA condensation capac-
ity, a desirable size distribution of ~240 nm, and a significant
macrophage-targeting ability. TPP-PPM/siTNF NPs significant-
ly inhibited TNF-α synthesis and secretion in tissue samples
from the DSS-induced colitis model ex vivo. Importantly,
TPP-PPM/siTNF NPs were efficiently taken up by macrophages,
with flow cytometry analysis demonstrating 29.5% uptake by
colon macrophages and insignificant uptake by epithelial cells.
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of TPP–PPM/siTNF NPs was suggested to reflect the combined
effect of the small particle size, surface PEGylation, and the
conjugation of mannose ligands. Similarly, Coco et al14
demonstrated in an ex vivo study that mannose-grafted PLGA
nanoparticles had the highest accumulation in inflamed colon
tissue from the DSS-induced colitis model, in comparison to
trimethylchitosan (TMC), PLGA and Eudragit® S-100 nanopar-
ticles. It should be noted that both of these studies did not
evaluate the formulation in an in vivo model of colitis—the
results of which would be of great interest.
To target macrophage galactose-type lectin (MGL) on
activated macrophages, Zhang et al144 prepared galactosylated
trimethyl chitosan-cysteine (GTC) nanoparticles for oral delivery
of mitogen-activated protein kinase kinase kinase kinase 4
(Map4k4) siRNA (siMap4k4), which is a key upstream mediator
of TNF-α production. siRNA loaded GTC nanoparticles were
prepared based on ionic gelation of GTC with anionic cross-
linkers, such as tripolyphosphate (TPP). Cellular uptake in
activated macrophages was significantly higher for GTC/TPP
nanoparticles compared to trimethyl chitosan-cysteine (TC)/TPP
nanoparticles, owing to galactose receptor-mediated endocyto-
sis. In vitro and in vivo studies showed effective inhibition of
TNF-α production and selective biodistribution of siRNA in
ulcerative tissue. Daily oral administration of siMap4k4 loaded
GTC/TPP nanoparticles significantly improved DSS-induced
colitis, as measured by body weight, histology, and myeloper-
oxidase activity.
A recent study by Laroui et al145 demonstrated that TNFα
siRNA can be efficiently loaded into nanoparticles made of
poly(lactic acid) poly(ethylene glycol) block copolymer (PLA–
PEG), and that grafting of a macrophage-specific ligand (Fab′
portion of the F4/80 Ab—Fab'-bearing) onto the nanoparticle
surface, via maleimide/thiol group-mediated covalent bonding,
increases the specificity of targeting to intestinal macrophages.
TNFα-siRNA-loaded nanoparticles significantly improved
DSS-induced colitis in vivo, following oral administration,
more efficiently when the nanoparticles were covered with Fab
′-bearing ligands compared to non-conjugated nanoparticles.
Grafting of Fab′-bearing ligands also improved nanoparticle
endocytosis as well as macrophage targeting ability, as indicated
by flow cytometry. It should be noted that this study did load the
nanoparticles into a colon-specific biodegradable hydrogel
(chitosan/alginate), which also enhanced its specific delivery to
the colon and protected the grafted ligand during GI transit
(discussed in Biodegradable nano-delivery systems).
The transferrin receptor (TfR) is another target that is
overexpressed in inflamed colon tissue, with elevated expression
in both the basolateral and apical membranes of enterocytes.89
This increase was observed in both colon biopsies from IBD
patients and excised colon tissue from colitis-induced rat models
of IBD.89,146 TfR levels are also elevated in activated immune
cells, including lymphocytes and macrophages.146 Harel et al147
investigated the ex vivo adhesion capacity of immunoliposomes
with anti-TfR antibodies conjugated to its surface to inflamed
mucosal tissue. The study reported mucopenetration of the
targeted formulation, with a 4-fold increase in uptake in inflamed
colon tissue from the TNBS-induced colitis model, compared tonon-inflamed colon tissue. This study does suggest a role for
mucosal transferrin receptor targeting in IBD; however additional
formulationmeasures would be required to protect the lipid-based
immunoliposomes from premature degradation in the GI tract
prior to evaluating the targeted nano-delivery system in vivo.
Epithelial CD98, a type II membrane glycoprotein heterodi-
mer, has been suggested as another promising target for IBD, as
it has been shown to play a vital role in intestinal inflammation.
Overexpression of CD98 on the surface of colonic epithelial cells
and macrophages promote the development and progression of
IBD.148-150 Recently, Xiao et al117 developed an orally delivered
hydrogel that releases CD98 siRNA loaded nanoparticles with
single-chain CD98 antibodies conjugated onto the surface
(200 nm). In mice with DSS-induced colitis and colitis induced
by transfer of CD4+CD45Rbhigh T cells to Rag−/− mice, oral
administration of the targeted nanoparticles significantly reduced
the overexpression of CD98 by colonic epithelial cells and
macrophages. Approximately 24% of colonic macrophages in
the mice had taken up the targeted nanoparticles within 12 hours
of administration. Severity of colitis was also significantly
reduced compared to the control groups, based on loss of body
weight, myeloperoxidase activity, inflammatory cytokine pro-
duction, and histological analysis. Overall, these studies
demonstrate that active targeting is a very promising approach
to enhancing drug accumulation and uptake into inflamed tissue
in IBD; however further in vivo studies are required to assess the
different targeting ligands and formulations for efficacy and
stability in animal models of colitis.
Future advances in colon targeted drug delivery
The design of nano-delivery systems has significantly
advanced the future for IBD therapy by improving the selective
targeting of active agents to sites of inflammation. Contrary to
most therapeutic regimens' utilizing oral administration, sys-
temic absorption is an undesirable delivery feature for these
drugs. Disease localization dictates the need for maximal
intestinal tissue drug exposure while systemic delivery should
be minimized to avoid unwanted side effects. This drug delivery
approach has been shown to increase therapeutic efficacy, lower
the therapeutically effective dose, reduce systemic side effects,
and has allowed the use of novel compounds with poor
physicochemical properties for oral delivery. This has been
achieved through specific biodistribution and accumulation in
the inflamed intestinal regions.
In order for the translational use of these carrier systems to the
clinic, several issues still have to be addressed. Firstly, the safety
of the different nano-delivery carriers following uptake need to
be explored further. Studies focused on the nanotoxicology of
these delivery systems in the human GI tract in IBD have been
limited, and is likely to vary according to the nanoparticle
material (e.g. polymer, lipids) and nanoparticle size.73 Secondly,
structural stability during GI transit would need to be further
optimized to prevent premature release in the stomach and small
intestine. Although in vitro and ex vivo stability, binding and
uptake studies provide valuable information for the nano-
delivery systems, these same parameters need to be validated
in vivo using well-established colitis models. Thirdly, increased
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further optimize this therapy. Based on the results to date, it is
very likely that a combination of pharmaceutical strategies that
have been discussed in this review is required for optimal
targeting to inflamed colon. Finally from a commercial
development point of view, simplification of drug delivery
design is required to allow efficient and reliable large-scale
manufacturing. In translating these findings from animals to
humans, we need to determine how to modify these formulations
so that they are appropriate for human administration. These
in vivo studies have been done in animal models of IBD, which
place limitations on the size and consistency of the dosage form
that can be administered orally. The practicability of designing
dosage forms that are both acceptable to humans and efficacious
needs to be further explored.
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